When the CDC paused diagnostic testing for rabies, mpox, and dozens of other infectious diseases in late March 2026, media coverage focused on two headline-grabbing infections: rabies and mpox. But experts who study infectious disease diagnostic capacity are increasingly drawing attention to a less-covered casualty of the staffing cuts: the CDC's malaria branch, which experienced cuts even deeper than the rabies and poxvirus laboratories.
According to HealthDay reporting on the broader CDC diagnostic cuts, the rabies and poxvirus labs each lost about half their staff — and the malaria branch saw even deeper cuts. CNN confirmed the same finding via the National Public Health Coalition, an organization of former and current CDC workers formed in the wake of the downsizing. The implications are directly tied to patient treatment outcomes, not just surveillance and epidemiology: because different species of malaria-causing Plasmodium parasites require different antimalarial drug regimens, failing to correctly identify the species can result in treatment failure or, in the case of Plasmodium falciparum — the most dangerous species — delayed effective treatment can be fatal.
Why This Matters
Malaria is not a disease most American clinicians encounter regularly. Approximately 2,000 cases are reported in the United States annually, almost entirely in travelers returning from malaria-endemic regions of sub-Saharan Africa, South Asia, and Southeast Asia. For a hospital or state health department that rarely sees malaria, having access to CDC diagnostic backup matters — because correctly identifying the Plasmodium species is not always straightforward and directly determines which antimalarial is appropriate.
The two most medically important distinctions, per CDC clinical guidance on malaria diagnosis and treatment:
Plasmodium falciparum is the most deadly species and requires specific, effective first-line treatment (artemisinin-based combination therapy such as artemether-lumefantrine). Delay or use of chloroquine in chloroquine-resistant P. falciparum infections can be fatal within days.
Plasmodium vivax and Plasmodium ovale can be treated with chloroquine, but also require primaquine to eliminate the liver-stage parasites (hypnozoites) that cause relapse — a treatment that requires G6PD testing before administration.
If a patient's malaria diagnosis relies on an incorrect species identification, the drug regimen selected may be wrong — not just ineffective, but potentially harmful in the case of species-specific toxicities or missed indications.
What We Know So Far
The CDC implemented a broad pause on diagnostic laboratory testing services in late March 2026, following what the agency described as a 20 to 25 percent reduction in overall CDC staffing as a result of the Trump administration's restructuring of federal health agencies. HHS described the testing pause as temporary and said services would resume "in the coming weeks."
According to CNN's reporting on the testing pause, the malaria branch's staffing reduction was confirmed to be particularly acute, with the National Public Health Coalition stating the malaria branch sustained even deeper cuts than the poxvirus and rabies laboratories, each of which lost approximately half their prior staff.
As of July 1, 2026, the full scope of what has been restored versus permanently reduced at the CDC's malaria diagnostic service remains publicly unclear. The CDC has not issued a comprehensive public update specifying which infectious disease diagnostic services have fully resumed, which remain reduced, and which have been permanently discontinued.
What Has Been Reported as Permanently Discontinued
According to reporting on the CDC's testing pause, some diagnostic services have been reported as permanently discontinued rather than temporarily paused, including measles immune response testing and leishmania species identification. Whether malaria speciation services have been affected in a permanent capacity, or whether reduced service capacity persists at levels that could affect turnaround time and diagnostic accuracy for imported malaria cases, has not been definitively confirmed in public-facing statements from CDC as of this writing.
What Doctors and Experts Say
Public health experts responding to the reporting on CDC diagnostic cuts have consistently noted that the practical danger from reduced malaria diagnostic capacity is not hypothetical — it is directly translatable into individual patient harm if a returning traveler with falciparum malaria receives delayed or incorrect treatment because definitive species identification was unavailable, slower, or less reliable.
Scott Becker, CEO of the Association of Public Health Laboratories, told the Associated Press that some specialized state labs — such as those in New York and California — have the ability to pick up the slack while CDC tests are on pause, but called the pauses "concerning, only if it's permanent."
State health departments that have historically relied on CDC as a reference laboratory for malaria speciation — particularly smaller state labs or those in regions that rarely see imported malaria cases and therefore have not maintained their own robust malaria diagnostic infrastructure — face the greatest practical gap.
Who Is Most Affected?
- Travelers returning from sub-Saharan Africa, South and Southeast Asia, and other malaria-endemic regions who develop fever and are diagnosed with malaria in the United States
- Hospital emergency departments and infectious disease services in states where malaria is so rare that local laboratory infrastructure for Plasmodium speciation is limited or absent
- State health departments that have historically referred complex or ambiguous malaria cases to CDC for confirmation
- Public health surveillance infrastructure relying on CDC to track emerging antimalarial resistance patterns in imported cases
What You Can Do Now
Clinicians: If you are treating a returning traveler with fever and suspected or confirmed malaria, contact your state health department to confirm current malaria diagnostic referral options, given uncertainty about CDC's current service capacity. CDC's clinical guidance on malaria diagnosis and treatment remains the authoritative resource; for complex cases, CDC can still be reached via the Malaria Hotline at 770-488-7788 (M–F, 9 a.m.–5 p.m. ET) or 770-488-7100 (after hours).
Clinicians: Review current CDC and WHO guidelines for empirical treatment of severe malaria while awaiting species confirmation, particularly the guidance for immediate treatment of presumptive falciparum malaria when delay carries clinical risk.
Travelers: Malaria prevention before travel is the most effective strategy — antimalarial prophylaxis, insect repellent, and bed nets significantly reduce infection risk. The CDC Yellow Book chapter on malaria remains the best pre-travel reference for clinicians advising international travelers.
Contact your state health department to understand current CDC diagnostic backup availability for any unusual or difficult infectious disease diagnostic case.
What Happens Next
The CDC has not issued a comprehensive public accounting of which diagnostic services have been fully restored, which remain reduced, and which have been permanently discontinued. MedicalDaily will report on any formal CDC announcement of service restoration status or any confirmed cases of treatment complications linked to delayed or inadequate malaria species identification.
The Bottom Line
The CDC's malaria diagnostic branch experienced staff cuts even deeper than the rabies and poxvirus laboratories during the spring 2026 testing pause — and in this case, the specific risk is directly tied to individual patient treatment outcomes, not just epidemiological surveillance. The wrong antimalarial for the wrong Plasmodium species is not just ineffective — it can be fatal in falciparum malaria. Clinicians treating returning travelers with malaria should verify current diagnostic referral pathways with their state health department rather than assuming CDC backup capacity is operating at full pre-cut levels.
